Most pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers Squibb, (NYSE: BMY) and both businesses have a lot to offer passive income investors too. As one of the world's most preeminent pharma conglomerates, Eli Lilly and its portfolio of products covers all sorts of illnesses, including Alzheimer's disease, diabetes, and different cancers. It also has 21 programs in phase 3 clinical trials, and another 21 in phase 2 trials.